The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.
复制标题
LeCanemab的负担能力，这是一种针对阿尔茨海默氏病的淀粉样蛋白靶向疗法：EADC-EC的观点。
DOI：
10.1016/j.lanepe.2023.100657
复制
发表时间：
2023-06
影响因子：
20.9
通讯作者：
Winblad, Bengt
中科院分区：
文献类型：
--
作者：
Joensson, Linus;Wimo, Anders;Handels, Ron;Johansson, Gunilla;Boada, Merce;Engelborghs, Sebastiaan;Froelich, Lutz;Jessen, Frank;Kehoe, Patrick Gavin;Kramberger, Milica;de Mendon, Alexandre;Ousset, Pierre Jean;Scarmeas, Nikolaos;Visser, Pieter Jelle;Waldemar, Gunhild;Winblad, Bengt
关键词：
Lecanemab是一种抗淀粉样蛋白抗体，对早期阿尔茨海默病（AD）的生物标志物和临床终点有影响，于2023年获得FDA加速批准，欧洲的监管审查正在进行中。我们估计，在27个欧盟国家中，可能有资格接受lecanemab治疗的人群为540万人。如果这种药物的价格与美国相似，每年的治疗费用将超过1330亿欧元，相当于欧盟药品总支出的一半以上。这种定价将是不可持续的;支付高价疗法的能力在各国之间存在很大差异。类似于美国宣布的定价可能会使一些欧洲国家的患者无法获得这种药物。在获得新型淀粉样蛋白靶向药物方面的差异可能会进一步加深整个欧洲在健康结果方面的不平等。作为欧洲阿尔茨海默病联盟执行委员会的代表，我们呼吁制定定价政策，使欧洲各地符合条件的患者能够获得重要的创新，并继续投资于研发。可能需要基础设施来跟踪常规护理中新疗法的使用情况和新的支付模式，以解决患者可负担性和不平等问题。
Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and regulatory review in Europe is ongoing. We estimate the population potentially eligible for treatment with lecanemab in the 27 EU countries to 5.4 million individuals. Treatment costs would exceed 133 billion EUR per year if the drug is priced similarly as in the United States, amounting to over half of the total pharmaceutical expenditures in the EU. This pricing would be unsustainable; the ability to pay for high-priced therapies varies substantially across countries. Pricing similarly to what has been announced for the United States may place the drug out of reach for patients in some European countries. Disparities in access to novel amyloid-targeting agents may further deepen the inequalities across Europe in health outcomes. As representatives of the European Alzheimer's Disease Consortium Executive Committee, we call for pricing policies that allow eligible patients across Europe to access important innovations, but also continued investments in research and development. Infrastructure to follow up the usage of new therapies in routine care and new payment models may be needed to address affordability and inequalities in patient access.
登录
查看更多内容
DOI：
10.1186/s13195-021-00813-8
发表时间：
2021-04-17
期刊：
Alzheimer's research & therapy
影响因子：
--
作者：
Swanson CJ;Zhang Y;Dhadda S;Wang J;Kaplow J;Lai RYK;Lannfelt L;Bradley H;Rabe M;Koyama A;Reyderman L;Berry DA;Berry S;Gordon R;Kramer LD;Cummings JL
通讯作者：
Cummings JL
影响因子：
4.4
作者：
Buzeti, Tatjana;Lima, Joana Madureira;Brown, Chris
通讯作者：
Brown, Chris
影响因子：
2.9
作者：
Epelbaum, Stephane;Paquet, Claire;Dubois, Bruno
通讯作者：
Dubois, Bruno
影响因子：
14
作者：
Gustavsson, Anders;Norton, Nicholas;van der Flier, Wiesje M.
通讯作者：
van der Flier, Wiesje M.
DOI：
10.1002/trc2.12295
发表时间：
2022
影响因子：
4.8
作者：
Cummings, Jeffrey;Lee, Garam;Nahed, Pouyan;Kambar, Mina Esmail Zadeh Nojoo;Zhong, Kate;Fonseca, Jorge;Taghva, Kazem
通讯作者：
Taghva, Kazem